1 min read
Add as a preferred source on Google

MapLight Therapeutics Posts $0.97 Q3 GAAP Loss Per Share, Beats Estimates

MapLight Therapeutics, Inc. had $463.4 million in cash, cash equivalents and investments as of Sept. 30.

A clear glass block rests beside a small dark metal weight / TokenPost.ai
A clear glass block rests beside a small dark metal weight / TokenPost.ai

MapLight Therapeutics, Inc. posted a third-quarter GAAP loss of $0.97 per share, beating estimates by $0.22.

The company had $463.4 million in cash, cash equivalents and investments as of Sept. 30, 2026.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…